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Abstract
Objectives—As an initial step toward our goal of developing a completely tissue-engineered 
larynx, the aim of this study was to describe and compare three strategies of creating tissue-
engineered muscle-polymer constructs for hemilaryngeal reconstruction.
Methods—Cartilage-mimicking polymer was developed from electrospun poly(D,L-lactide-co-ε-
caprolactone) (PCL). Primary muscle progenitor cell cultures were derived from syngeneic F344 
rat skeletal muscle biopsies. Twenty F344 rats underwent resection of the outer hemilaryngeal 
cartilage with the underlying laryngeal adductor muscle. The defects were repaired with muscle 
stem cell–derived muscle–PCL constructs (5 animals), myotubc-derived muscle–PCL constructs 
(5 animals), motor end plate–expressing muscle–PCL constructs (5 animals), or PCL alone 
(controls; 5 animals). The outcome measures at 1 month included animal survival, muscle 
thickness, and innervation status as determined by electromyography and immunohistochemistry.
Results—All of the animals survived the 1-month implant period and had appropriate weight 
gain. The group that received motor end plate–expressing muscle–PCL constructs demonstrated 
the greatest muscle thickness and the strongest innervation, according to electromyographic 
activity and the percentage of motor end plates that had nerve contact.
Conclusions—Although all of the tissue-engineered constructs provided effective 
reconstruction, those that expressed motor end plates before implantation yielded muscle that was 
more strongly innervated and viable. This finding suggests that this novel approach may be useful 
in the development of a tissue-engineered laryngeal replacement.
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INTRODUCTION
Our ability to relay emotions, convey our personalities, and communicate effectively is 
intricately associated with our voicing ability. Neoplastic and traumatic injuries of the larynx 
can result in devastating voice impairment. Currently, laryngeal cancer affects more than 
12,000 new individuals in the United States each year,1 and many of those patients undergo 
partial laryngectomy or total laryngectomy with resultant sacrifice of voice quality. 
Iatrogenic traumatic avulsion of the vocal folds is another common source of irreversible 
vocal fold damage, with up to 6.3% of general anesthetic endotracheal intubations 
associated with traumatic injuries of the laryngopharynx.2 Non-iatrogenic traumatic injury to 
the larynx is less common, affecting only 1 in 30,000 patients who present to the emergency 
department3; however, the injuries are often severe and likely to lead to permanent voice 
loss. These postoncologic or posttraumatic laryngeal injuries can be especially devastating 
to patients, because the lack of laryngeal airway protection and/or patency often renders the 
patients dependent on a gastrostomy and/or tracheostomy tube, in addition to causing them 
severe dysphonia.
To date, we have no clinically feasible options for replacing the larynx with a dynamic 
organ after neoplastic or traumatic partial or total laryngectomy. Microvascular or pedicled 
flaps are suboptimal reconstructive options for the vocal folds in that they require extensive 
surgery, involve donor site morbidity, and fail to restore dynamic motion. Although tissue-
engineered muscle may be a future reconstructive option for the larynx, the literature 
suggests that inadequate innervation and muscle atrophy have been hurdles to this 
technology in other sites, such as the limbs.4 No previous studies have investigated the 
innervation and posttransplant survival of tissue-engineered muscle used for muscle 
replacement in the larynx. In the knowledge that denervated laryngeal adductor muscles 
characteristically receive spontaneous reinnervation even after complete transection of the 
recurrent laryngeal nerve (RLN),5–7 we hypothesized that tissue-engineered muscle would 
survive and become actively innervated when used for adductor muscle replacement in the 
larynx. In addition, evidence suggests that aneural motor end plates on myofibers in vivo 
will direct and promote axonal outgrowth to the aneural end plates and thereby lead to new 
neuromuscular junctions.8 Thus, we hypothesized that tissue-engineered muscle-polymer 
implants that are created with motor end plate–expressing (MEE) myotubes (MTs) would 
result in enhanced innervation of the tissue-engineered muscle beyond that of muscle stem 
cell (MSC)–derived or MT-derived muscle–polymer implants alone. Specifically, the goal 
of this project was to test three different muscle-polymer implant construction strategies to 
determine whether one strategy would consistently provide a stable, nonimmunogenic, 
innervated tissue-engineered myochondral replacement for reconstruction of muscle and 
cartilage hemilaryngeal defects. This initial study is critical to our group’s long-term goal of 
developing a completely tissue-engineered larynx for postlaryngectomy patients.
METHODS
TISSUE-ENGINEERED MUSCLE
Primary Muscle Progenitor Cell Cultures—Approximately 4 g of F344 rat skeletal 
muscle (see Animal Surgeries, below) was transferred to initial myogenic culture medium 
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(IMCM) F-10 culture medium (Invitrogen, Life Technologies, Carlsbad, California; catalog 
number 11550–043) supplemented with 20% fetal bovine serum (HyClone Laboratories, 
Thermo Fisher Scientific, Waltham, Massachusetts; SH30070.03), 1% penicillin/
streptomycin/amphotericin B (Cellgro; Mediatech, Inc, Manassas, Virginia; 30–004-CI), and 
1% chicken embryo extract (SeraLab, Haywards Heath, England; CE-650-J). The muscle 
was minced into small pieces and digested in 0.2% collagenase type I (collagenase type 1–
filtered; Worthington Biochemical Corp, Lakewood, New Jersey; LS004214) in IMCM 
within a shaking water bath at 37°C for 2 hours. The IMCM was added to digested muscle 
to terminate the reaction, and individual fibers were dissociated by rigorous pipetting. 
Digested tissue was filtered through a 300 μmol/L pore-size strainer and washed 3 times 
with IMCM. The pellet was resuspended in IMCM, and the muscle fibers were transferred 
into 3 wells of a 0.1% gelatin-coated 6-well culture plate (gelatin from porcine skin, type A; 
Sigma-Aldrich, St Louis, Missouri; G1890). Single fibers were confirmed by phase 
microscopy, and plates were left in a 5% carbon dioxide incubator at 37°C overnight. To 
prevent potential overgrowth of fibroblasts, we transferred the supernatant containing 
nonadhered muscle progenitor cells (MPCs) into 3 new wells of a 0.1% gelatin-coated 6-
well plate after 24 hours. The medium was changed every other day. When primary cultures 
reached 70% confluency, they were passaged to prevent MT formation. The growth medium 
was changed to a myogenic culture medium (MCM; F-10 culture medium; Gibco, Grand 
Island. New York; 11550–043) supplemented with 10% fetal bovine serum (HyClone 
Laboratories; SH30070.03) and 1% penicillin/streptomycin (HyClone Laboratories; 
J110381) after the second passage. The MPCs, now in the form of MSCs (myoblasts and 
satellite cells) were maintained in 100-mm plates. MyoD expression and lack of MT-specific 
elongation confirmed a pure MSC population.
Strategies for Engineering Muscle-Polymer Implants In Vitro—Scaffolds of 
poly(D,L-lactide-co-ε-caprolactone) (PCL) were created as described in PCL Polymer 
Construction, below. Each scaffold was cut into 3 × 4-mm pieces and sterilized in 70% 
alcohol for 5 minutes. The scaffolds were rinsed in phosphate-buffered saline solution (PBS) 
and left under an ultraviolet light hood overnight for sterilization. Each PCL piece was 
seeded with approximately 8 ×105 MSCs within a 48-well plate in 300 μL MCM, and the 
plate was left on a rocker (Infinity Rocker; Nextadvance, Averill Park, New York) in a 37°C 
5% carbon dioxide cell incubator for 1 hour of rocking at 15 cycles per minute. The seeding 
was repeated every day for 3 days. In the MSC group, cells were consistently passaged when 
the cell culture plate demonstrated 70% confluency, thereby preventing MT formation. In 
the MT group, the culture medium was switched to F10 supplemented with 10% horse 
serum on day 4 to induce MT formation. In the MEE group, the culture medium was 
supplemented with 10% horse serum to induce MT formation; in addition, our laboratory’s 
optimized combination of additives to induce motor end plate expression, including 
acetylcholine chloride (Ach, 40 nmol/L; Tocris Bioscience, Bristol, England; 2809), agrin 
(10 nmol/L; R&D Systems, Minneapolis, Minnesota; 550-AG), and neuregulin (NRG1, 2 
nmol/L; R&D Systems; 378-SM), was added to this medium, and the medium was changed 
every 3 days. Expression of motor end plates was confirmed with Alexa Fluor 594 
conjugated α-bungarotoxin (Molecular Probes, Life Technologies; B13423; dilution 1:100) 
incubation for 1 hour, followed by visualization with the Olympus Flowviewer 1,000 mpe 
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confocal/2-photon microscope (Fig 1). In all treatment groups, the muscle-polymer 
constructs were washed with PBS 6 days after varying the culture medium, and transferred 
to the animal operating room for implantation by sterile technique.
PCL POLYMER CONSTRUCTION
Scaffold Synthesis—The PCL (inherent viscosity, 1.29 dL g−1 in chloroform; 
Absorbable Polymers, Birmingham, Alabama) scaffolds were fabricated via electrospinning 
with use of a conventional setup comprising a high-voltage source (ES50P-10W/DAM; 
Gamma High Voltage Research, Ormond Beach, Florida), a syringe pump (Legato 200; KD 
Scientific, Holliston, Massachusetts), and a grounded stainless steel collecting mandrel as 
previously described.9 In brief, the electrospinning processing parameters, including the 
solution concentration (10 to 20 wt% PCL) and the field strength (voltage), were optimized 
to achieve defect-free fibrous structures. Both the flow rate and the spinneret-to-collector 
distance were kept constant at 1 mL/h and 18 cm, respectively. The optimum defect-free and 
homogeneous fiber diameter scaffold was obtained by dissolving PCL in 
hexafluoroisopropanol (HFP; Sigma-Aldrich) overnight under stirring conditions at 150 
mg/mL. The formulation was loaded in a plastic syringe fitted with a 27-gauge stainless 
needle and electrospun at 10 kV. The scaffolds were kept at room temperature for 2 days in 
a vacuum desiccator to remove any residual solvent.
Scaffold Characterization—Scanning electron microscopy (SEM; JSM-5310LV; JEOL, 
Tokyo, Japan) was used to assess fiber morphology and the overall scaffold porous structure 
that would facilitate myoblast or MT attachment. Briefly, small samples were excised from 
each of the scaffolds obtained in the optimization process. Then, samples were mounted on 
aluminum stubs, sputter-coated with gold, and imaged at 15 keV. The average fiber diameter 
was calculated from measurements obtained with Image J 1.40G software (US National 
Institutes of Health) on 3 distinct SEM images. Mechanical testing of the optimized scaffold 
(ie, PCL at 15 wt%) was performed by uni-axial microtensile testing (eXpert 5601; Admet, 
Norwood, Massachusetts) on rectangular samples (15 × 3 mm) at a cross-head speed of 5 
mm/min. Similarly, the mechanical strength of the rat native laryngeal cartilage was also 
measured. The maximum load needed to produce fracture was recorded (N/mm2 = MPa) on 
dedicated software. The results are reported as mean ± SD.
ANIMAL SURGERIES
The study protocol was approved by the Indiana School of Medicine Animal Care and Use 
Committee, and institutional guidelines, in accordance with the National Institutes of Health 
guidelines, were followed for the handling and care of the animals. Because Fischer 344 
males are syngeneic, 1 donor animal was used to create tissue-engineered constructs for 20 
study animals.
Muscle Harvest—One Fischer 344 male rat (Harlan Laboratories, Indianapolis, Indiana) 
was anesthetized with intraperitoneal administration of ketamine hydrochloride (75 mg/kg) 
and xylazine hydrochloride (10 mg/kg), and a 1-cm vertical cervical incision was created at 
midline. Dissection proceeded to the cervical muscles, and approximately 4 g of cervical 
muscle (strap and sternocleidomastoid muscles) was harvested and placed immediately in 
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IMCM. The steps outlined in Primary Muscle Progenitor Cell Cultures, above, were then 
followed.
Partial Laryngectomy Procedures—Twenty Fischer 344 male rats (Harlan 
Laboratories) were anesthetized with intraperitoneal administration of ketamine 
hydrochloride (75 mg/kg) and xylazine hydrochloride (10 mg/kg), and underwent resection 
of the left lateral thyroid cartilage with as much adductor muscle (lateral and medial 
thyroarytenoid, alar cricoarytenoid, and lateral cricoarytenoid) as could be safely removed 
without violation of the inner mucosa. Mucosal violation was avoided to minimize infection 
risk. Animals were randomized to undergo repair with PCL polymer scaffolds alone (5 
animals; control or PCL group), MSC-based muscle–polymer constructs (5 animals; MSC 
group), MT-based muscle–polymer constructs (5 animals; MT group), or MEE muscle–
polymer constructs (5 animals; MEE group; Fig 2). After the implant was secured, the strap 
muscles were reapproximated and the skin was closed with 5-0 Vicryl suture.
Evaluation Under Anesthesia—After 1 month, the animals were returned to the 
operating room to be placed under anesthesia with inhalational isoflurane, which was titrated 
to permit stimulation-induced laryngospasm. Under anesthesia, laryngeal electromyography 
(LEMG; Niking Viking Quest electromyography machine, Madison, Wisconsin) was used 
to test the adductor muscle complex and the posterior cricoarytenoid (PCA) muscles 
bilaterally with a 25-gauge bipolar concentric needle, with use of an amplitude of 50 to 100 
μV, 10- to 100-ms sweep speeds, and a clamp on exposed lateral neck muscle for grounding. 
To ensure optimal needle insertion, we created a neck incision and exposed the larynx to 
allow direct visualization of the implant and laryngeal anatomy during the LEMG. Needle 
insertion into the PCA muscle was done directly while the larynx was gently rotated 
contralaterally. The adductor complex was tested via the cricothyroid membrane. The PCA 
and adductor muscles were tested first so that firing patterns in the engineered muscle could 
be assessed relative to the native laryngeal muscles. To determine whether the tissue-
engineered muscle constructs were firing congruently with native adductor and/or PCA 
muscles, we performed LEMG at 100 μV and 100-ms sweep speeds, and captured patterns 
of firing from the tissue-engineered muscle and compared them to those from the adductor 
complex and the PCA muscle. The PCA muscle’s highly characteristic inspiratory bursts of 
activity (Fig 3F) allowed tracings to be directly compared and inspiratory firing to be readily 
identified. The tissue-engineered muscle was tested by inserting the needle into the luminal 
side of the implant and identifying crisp areas of signaling while maintaining contact with 
the polymer. Qualitative comparison of recruitment was done during laryngospasm at 50 μV 
and 10-ms sweep. As the isoflurane anesthesia was lightened (by lowering the percentage of 
isoflurane), the animals went into laryngospasm as a 25-gauge needle was inserted via the 
cricothyroid membrane into the laryngeal airway. The LEMG needle was inserted into the 
muscle of interest to obtain a recording, and the isoflurane levels were then increased again 
to deepen the animals’ anesthesia. After the LEMG was completed, the animal was placed 
under deeper anesthesia with intraperitoneal administration of ketamine hydrochloride (75 
mg/kg) and xylazine hydrochloride (10 mg/kg) and euthanized. The larynx, implant, and 
strap muscles overlying the implant were harvested en bloc for further analysis.
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IMMUNOHISTOCHEMISTRY
Percentage of Motor End Plates With Neuronal Contact—After harvested 
specimens were incubated for a 12-hour period with 4% paraformaldehyde at 4°C, they were 
transferred into 30% sucrose at 4°C for an additional 24 hours. Axial cryosectioning was 
performed with 12-μm thickness on 3% gelatin-coated slides. The cryosections were washed 
in PBS 3 times. They were incubated in 0.3 mol/L glycine in PBS for 20 minutes. The 
sections were then permeabilized in 0.1% Triton X-100 in PBS for 20 minutes. They were 
washed with PBS 3 times and then blocked with 4% goat serum for 1 hour. After an 
overnight incubation at 4°C with rabbit polyclonal class III β-tubulin (Covance, Richmond, 
California; PRB-435p) at 1/1,000 dilution, slides were incubated with Alexa Fluor 488 
conjugated goat anti-rabbit immunoglobulin G secondary antibody (Invitrogen; A11034) for 
1 hour. To visualize the motor end plates in the same sections, we incubated them with 
Alexa Fluor 594 conjugated α-bungarotoxin (Molecular Probes; B13423; dilution 1:100) for 
1 hour. The sections were observed with the Olympus Flowviewer 1,000 mpe confocal/2-
photon microscope.
Assessment of Rejection Markers—Specimen fixation and cryosectioning were 
performed as described in the preceding paragraph. The sections were hydrated by 2 
changes of PBS. The slides were immersed in Liberate Antibody Binding (LAB) epitope 
retrieval solution (Polysciences, Inc, Warrington, Pennsylvania; 24310) for 15 minutes, and 
then endogenous peroxidase was inactivated by incubation with 3% hydrogen peroxide 
(Sigma-A1-drich; H1009) in methanol for 5 minutes. To block nonspecific binding sites, we 
incubated the sections with 1.5% normal horse serum (Vectastain ABC kit; mouse 
immunoglobulin G; Vector Laboratories, Burlingame, California; PK-6102) in a 
humidification chamber for 30 minutes. The sections were incubated with monoclonal 
antibodies overnight at 4°C at 1:50 dilution: mouse anti-CD3 antibody (Abcam, Cambridge, 
Massachusetts; B355.1; ab8671), mouse anti-CD4 antibody (Abcam; CA-4; ab82252), and 
mouse anti-CD8a antibody (BD Biosciences, San Jose, California; 554854). After being 
washed 3 times with PBS, the sections were incubated with anti-mouse biotinylated 
secondary antibody for 30 minutes at room temperature. After being washed twice with 
PBS, the sections were incubated with Vectastain Elite ABC reagent (Vectastain ABC kit; 
mouse immunoglobulin G; Vector Laboratories, PK-6102) for 30 minutes at room 
temperature. After washings with 2 changes of PBS, the sections were incubated with 
peroxidase substrate solution (chromogenic substrate 3,3′-diaminobenzidine 
tetrahydrochloride; Sigma-Aldrich; D5905) for 1 minute. The sections were then 
counterstained in modified Harris hematoxylin (Richard-Allan Scientific, Thermo Fisher 
Scientific; 72704) for 1 minute before dehydration and mounting (Eukitt; Election 
Microscopy Sciences, Hatfield, Pennsylvania; 15322).
MUSCLE THICKNESS
Specimen fixation and cryosectioning were performed as described above, in the first 
paragraph of Immunohistochemistry. For each animal, 6 axial sections of 12-μm thickness 
were created through the mid-portion of the implant to be used for hematoxylin-eosin 
staining. The sections were rehydrated for 1 minute in water followed by 1 minute of 
staining with modified Harris hematoxylin and 1 minute of staining with 0.25% eosin 
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(Fisher Scientific; SE22-500D). The sections were dehydrated with alcohol, cleared with 
xylenes, and mounted by Eukitt. The slides were then assessed under microscopy, and 
images were captured of the slides that demonstrated the maximal muscle-polymer thickness 
for each animal. Image J was used to measure the thickness of the tissue-engineered muscle 
on the surface of each implant at 3 sites, and the average maximum muscle thickness and 
mean thickness were then calculated for each specimen.
STATISTICAL ANALYSIS
Student’s t-test was used to compare changes in the treatment groups to those in the control 
group. Analysis of variance was used to compare differences between treatment groups. For 
all statistical tests, significance was set at a p level of less than 0.05.
RESULTS
SCAFFOLD CHARACTERIZATION
Figure 4A–F shows representative SEM images of nonoptimized electrospun PCL fibers at 
different processing parameters. The mean fiber diameter was strongly dependent on the 
processing conditions used. The nonoptimized electrospun mean fiber diameters ranged 
from 645 nm to 3.9 μm. Specifically, we observed that increasing both the polymer solution 
concentration and the field strength (voltage) led to an increase in fiber diameter. More 
important, even though PCL at 150 mg/mL yielded thicker fibers than did the 100 mg/mL 
solution at the same voltage (645 ± 641 nm), a narrower fiber distribution was seen in this 
optimized condition (1.62 ± 0.41 μm). Furthermore, all of the different scaffolds revealed an 
open porosity and an interconnected structure; however, the SEM images for the optimized 
condition suggest larger pore sizes (approximately 15 to 20 μm), which in turn would allow 
for better cell infiltration. Thus, 15 wt% PCL with a voltage of 10 kV and a flow rate of 1 
mL/h demonstrated the ideal scaffold characteristics (Fig. 4G,H), with porosity and fiber 
thickness that promote cellular and vascular ingrowth, and fiber diameters that provide 
adequate structural support for the hemilarynx. Table 1 shows the PCL scaffolds’ 
mechanical data recorded before implantation, which demonstrated load tolerance and 
tensile strength similar to those of native rat cartilage.
ANIMAL SURGERIES
One animal in the MT group failed to awaken from the initial surgery because of anesthesia-
related problems, and the remaining 19 animals survived. All surviving animals steadily 
gained weight in the postoperative period.
LEMG—At 1 month after implantation, LEMG demonstrated the most motor unit potentials 
in the MSC and MEE groups, demonstrated no activity in the PCL group, and demonstrated 
minimal activity in the MT group (Fig. 3). In all animals, the LEMG activity was 
synchronized with contralateral adductor muscle firing — a finding suggesting that the 
tissue-engineered muscle had received adductor innervation.
Percentage of Motor End Plates With Neuronal Contact—For each group, we 
analyzed 6 images of axial sections from each specimen and determined the percentage of 
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motor end plates with nerve contact after counting a minimum of 150 end plates for each 
group. There were no motor end plates detected in the PCL group, whereas the other groups 
all demonstrated motor end plates (Fig. 5). The mean percentages of motor end plates with 
nerve contact were 82.4%, 65.8%, and 94.8% for the MSC group, the MT group, and the 
MEE group, respectively (Table 2).
Muscle Thickness—The tissue-engineered myofibers were characterized by a 
disorganized appearance that allowed the tissue-engineered muscle to be readily discerned 
from any residual native adductor muscle located deep to the implant (Fig. 6). The mean 
thicknesses from the inner border of the PCL implant to the outer border of the tissue-
engineered muscle were 587.3 μm, 680.2 μm, and 750.3 μm for the MSC group, the MT 
group, and the MEE group, respectively (Table 2).
Assessment of Rejection Markers—Rejection markers failed to demonstrate 
immunorejection of any specimens, although a nonspecific inflammatory reaction could be 
detected around the implant in many sections (Fig. 7).
DISCUSSION
The goal of this project was to test three different muscle-polymer implant fabrication 
strategies to determine whether any approach could provide a stable, nonimmunogenic, 
innervated tissue-engineered replacement for reconstruction of muscle and cartilaginous 
hemilaryngeal defects. The tissue-engineered muscle in the MSC group was created from 
premature MPC subtypes consisting of satellite cells and myoblasts, in the MT group the 
muscle was derived from unmodified mature MPCs called MTs (multinucleated muscle 
cells), and in the MEE group the muscle was derived from MTs modified to express motor 
end plates.10–12 We anticipated that a 1-month implantation period would be adequate to 
assess the innervation of the implants for two reasons: 1) spontaneous reinnervation in the 
rat occurs much earlier than that seen in humans in models of RLN injury,7,13,14 and 2) since 
the RLN was not actually transected in this model, innervation of the muscle-polymer 
implants likely occurred via axonal spouting and regeneration of adductor RLN fibers 
injured during the myectomy procedure, and the close proximity of the regenerating axons 
and the tissue-engineered muscle likely facilitated rapid implant innervation. We 
hypothesized that the increased expression of motor end plates in the MEE group may lead 
to postmyectomy axonal sprouting and regeneration directed toward the aneural end plates, 
as occurs after acute denervation injury.7 According to the percentage of motor end plates 
with nerve contact, the MEE group did demonstrate significantly greater innervation than 
did the other groups; nearly 95% of the end plates had nerve contact at just 1 month. The 
LEMG activity demonstrated bursts of motor unit potentials that fired in synchrony with the 
native adductor complex, suggesting that the muscle might have functional contraction if a 
more organized network of muscle were engineered. Interestingly, the MSC group also 
demonstrated a very high rate of innervation and a high prevalence of motor end plates 
within the myofibers, with more than 82% of motor end plates demonstrating neuronal 
contact. The primitive and reparative nature of the MSCs may have resulted in this innately 
strong tendency to develop neuromuscular junctions in vivo. However, MSCs are also 
characterized by their postimplantation differentiation and fusion to form MTs, which then 
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fuse to form myofibers in vivo. As many MSCs (myoblasts) are required for the formation 
of a single multinucleated MT, it might be anticipated that the fusion process would lead to a 
loss of muscle volume when MSC-based constructs are implanted in vivo. Indeed, the 
postimplantation thickness of the tissue-engineered muscle was significantly lower in the 
MSC group than in the MT and MEE groups. For both of the MT-based groups (MT and 
MEE), the thickness of the muscle was closely associated with the innervation status of the 
engineered muscle. These findings suggest that tissue-engineered muscle thickness 
(survival) is directly dependent on innervation, and that atrophy will occur without 
innervation, just as atrophy occurs when innate myofibers become acutely denervated.13,14
The PCL scaffold in the current model displays clear advantages and disadvantages. The 
advantages of the PCL scaffold include its ability to be fabricated expediently in large 
quantities without any donor tissues (as required with alternatives such as decellularized 
cartilage), its ability to foster myogenic cell growth and adherence, and its stability after 
implantation. Among the disadvantages, there was evidence of a diffuse inflammatory 
infiltrate surrounding the PCL, likely mediating gradual bio-absorption of the implant, as is 
known to occur.15 In addition, because the electrospun PCL scaffold provided the 
foundation for myogenic cell adhesion, the resultant tissue-engineered muscle displayed a 
multidirectional interwoven network similar to that of the underlying polymer. Because our 
future goal is to create a functional myochondral replacement, the muscle will need to be 
organized and unidirectional, and thus a scaffold material will need to be developed to better 
support the desired organization and directionality of the tissue-engineered muscle. 
Electrospinning techniques can be customized to create a uniform, striated inner scaffold 
surface that would likely improve the organization of the myofibers. To improve myofiber 
organization, our laboratory is not only further tailoring the fabrication process to yield 
nanosized and aligned fibers, but also investigating the use of decellularized larynges as a 
framework material for laryngeal tissue engineering. Future studies will incorporate stem 
cell–derived cartilage, muscle, and vibratory epithelium,16,17 thus paving the way to our 
long-term goal of developing a completely tissue-engineered larynx.
CONCLUSIONS
The current study demonstrates that a tissue-engineered myopolymer implant derived from 
autologous MPCs can be used for myochondral hemilaryngectomy reconstruction. 
Furthermore, this report introduces a novel method of inducing expression of motor end 
plates on myogenic cells in vitro that results in a significant advance in the innervation and 
viability of tissue-engineered muscle. These experiments represent essential initial steps 
directing us toward our long-term goal of developing a functional tissue-engineered 
laryngeal replacement.
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Fig 1. 
Motor end plate formation in culture. For in vitro visualization, muscle progenitor cells in 
this Figure are expressing enhanced green fluorescent protein (EGFP: green), although 
tissue-engineered muscle-polymer implants used for implantation were created with 
unmodified primary muscle stem cells (MSCs). A) When primary cultures were passaged to 
prevent myotube (MT) differentiation (as described in Primary Muscle Progenitor Cell 
Cultures section) and incubated with acetylcholine, agrin, and neuregulin, α-bungarotoxin 
staining depicted expression of acetylcholine receptors (AChRs) on individual MSC surface 
(gray). B) To induce multinucleated MT formation (as described for MT group, ie, group 
with MT-derived muscle–PCL [poly(D,L-lactide-co-ε-caprolactone)] constructs), we 
incubated cells in nutrient-poor microenvironment (10% horse serum) that induced 
myoblasts to fuse with one another (arrowheads demarcating contact points between fusing 
myoblasts). In MEE group (group with motor end plate–expressing muscle–PCL 
constructs), cells were incubated in MT medium with acetylcholine, agrin, and neuregulin 
(as described in Methods) to induce AChR formation. Note that whereas AChRs formed on 
the MSC surface (in A), developing MTs formed mature motor end plates (arrow).
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Fig 2. 
Intraoperative implant positioning. Left hemilaryngeal cartilage with underlying adductor 
muscle has been resected, with care taken to avoid intralaryngeal mucosal violation. Implant 
(black arrow) is secured with tissue-engineered muscle facing inward and outer PCL 
scaffold adjacent to native right hemilaryngeal cartilage (white solid arrow). PCL scaffold is 
slightly oversized to overlap cricothyroid membrane above cricoid cartilage (white dotted 
arrow).
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Fig 3. 
Representative laryngeal electromyography (EMG) findings. To detect relative differences 
in activity levels, we recorded laryngeal EMG tracings with amplitude of 50 μV and sweep 
speed of 10 ms (A–E). To demonstrate inspiratory firing of posterior cricoarytenoid (PCA) 
muscle, we recorded tracing at amplitude of 50 μV and sweep speed of 100 ms (F). A) In 
negative PCL control, no active motor unit potentials were detected because of absence of 
significant tissue-engineered muscle on implant. Fact that insertional activity was 
reproducible (bracket) when EMG recording needle was inserted directly into PCL implant 
suggests that sparsely populated noninnervated muscle cells had infiltrated scaffold. B) 
MSC group (group with MSC-based muscle–polymer constructs) demonstrated low levels 
of motor unit potentials that fired in synchrony with contralateral adductor muscle during 
laryngospasm. No inspiratory firing was noted. C) MT group (see Fig 1 for definition) 
demonstrated qualitatively less recruitment upon laryngospasm, and as in MSC group, there 
were no inspiratory bursts of activity. D) MEE group (see Fig 1 for definition) demonstrated 
bursts of motor unit potentials that were firing with intensity and timing similar to those of 
contralateral native adductor muscle complex. As in MSC and MT groups, no inspiratory 
firing was detected. E) Native adductor muscle complex demonstrated bursts of motor unit 
potentials during laryngospasm and no active firing on inspiration. F) Although relative 
degree of recruitment did not differ significantly between adductor complex and PCA 
muscle, PCA muscle demonstrated characteristic inspiratory bursts of activity that were 
absent in native adductor complex and tissue-engineered muscle.
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Fig. 4. 
PCL implants electrospun with different porosities. A–H) Representative scanning electron 
microscopy (SEM) images of electrospun fibers obtained during optimization process. A,B) 
PCL fibers obtained from 100 mg/mL solution with electrospinning parameters 10 kV, 18 
cm, and 1 mL/h. C,D) PCL fibers obtained from 100 mg/mL solution with electrospinning 
parameters 18 kV, 18 cm, and 1 mL/h. E,F) PCL fibers obtained from 200 mg/mL solution 
with electrospinning parameters 18 kV, 18 cm, and 1 mL/h. G,H) Representative SEM 
images of optimized PCL fibers obtained from 150 mg/mL solution with electrospinning 
parameters 10 kV, 18 cm, and 1 mL/h. Note larger open pores and more homogeneous fiber 
diameter at these processing parameters in comparison to other, nonoptimal conditions (A–
F). Insets (B,D,F,H) show higher-magnification images (5,000×).
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Fig. 5. 
Motor end plates with neuronal contact. Immunohistochemical analysis was performed with 
fluorescent red secondary antibody to detect motor end plate–specific bungarotoxin, and 
fluorescent green secondary antibody was used to identify neuronal specific beta3-tubulin. 
A) MSC group demonstrated scattered areas of motor end plates (red; arrows) with scattered 
neuronal ingrowth (green) between myoblast cells. B) MT group demonstrated only rare 
motor end plates (red; arrows), and there was dense neuronal network (green) around 
myotubes. C) MEE group demonstrated both dense areas of motor end plates (red; arrows) 
throughout and dense neuronal infiltrate surrounding myotubes. D) PCL group, because of 
absence of tissue-engineered muscle on implant, failed to demonstrate motor end plates 
(red), although rare neuronal ingrowth (green) was detected within connective tissue 
adjacent to implant.
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Fig. 6. 
Muscle thickness (hematoxylin-eosin staining). A) Axial section of native rat larynx with 
thyroid cartilage intact (arrows). B) Section from MEE group at 1 month after implantation. 
Tissue-engineered muscle is outlined, and arrows demarcate polymer scaffold.
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Fig. 7. 
Inflammation and immunoreactivity. Although many implants demonstrated mild 
inflammatory infiltrate at surgical site, there was no evidence of immune-mediated rejection 
in any specimens. Rows represent anti-CD3 (A–C), anti-CD4 (D–F), and anti-CD8 (G–I) 
staining used to detect lymphocytes that mediate immune rejection. Left column (A,D,G) 
shows representative negative controls, middle column (B,E,H) shows representative study 
samples, and right column (C,F,I) shows positive controls (spleen). Fact that all study 
groups demonstrated absence of CD3, CD4, and CD8 lymphocytes suggests there was no 
specific rejection of tissue-engineered implants.
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TABLE 1
MECHANICAL CHARACTERISTICS OF PCL IMPLANT IN COMPARISON TO NATIVE RAT 
CARTILAGE
Native Rat Cartilage PCL Implant Before Implantation
Maximum load (N) 1.61 ± 0.3 1.99 ± 0.3
Tensile strength (MPa) 1.57 ± 0.4 1.79 ± 0.3
PCL — poly(D,L-lactide-co-ε-caprolactone).
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TABLE 2
INNERVATION STATUS AND MUSCLE THICKNESS FOR EACH GROUP
MSC Group MT Group MEE Group
Mean motor end plate count 82.6 44.3 87.3
Mean % of motor end plates with nerve contact 82.4% 65.8% 94.8%
Mean tissue-engineered muscle thickness (μm) 587.3 680.2 750.3
All data are based on review of 6 slides per animal.
MSC — muscle stem cell; MT — myotube; MEE — motor end plate–expressing. (See Partial Laryngectomy Procedures for further description of 
groups.)
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